• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/26 4:03:21 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email
    htfl-20260514x8k
    false000146452100014645212026-05-142026-05-14

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ______________________

    FORM 8-K

    ______________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2026

    ______________________

    Heartflow, Inc.

    (Exact name of Registrant as Specified in Its Charter)

    ______________________

    Delaware

    001-42790

    26-0506743

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

    135 Main Street, Suite 1000

    San Francisco, California 94105

    (Address of Principal Executive Offices) (Zip Code)

    (650) 241-1221

    (Registrant’s Telephone Number, Including Area Code)

    331 E. Evelyn Avenue, Mountain View, CA 94041

    (Former Name or Former Address, if Changed Since Last Report)

    ______________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ¨

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

    HTFL

    The Nasdaq Stock Market LLC

    (Nasdaq Global Select Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company  x

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨


    Item 2.02 Results of Operations and Financial Condition.

    On May 14, 2026, Heartflow, Inc. issued a press release regarding its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits.

    (d)Exhibits.

    Exhibit No.

    Description

    99.1

    Press Release of Heartflow, Inc. issued on May 14, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    The information contained in Items 2.02 and 9.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


    ‎


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    HEARTFLOW, INC.

    Date: May 14, 2026

    By:

    /s/ Vikram Verghese

    Vikram Verghese

    Chief Financial Officer

    Get the next $HTFL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    5/4/2026Outperform
    William Blair
    1/28/2026$38.00Overweight
    Wells Fargo
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $261,266 worth of shares (9,219 units at $28.34) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/20/26 5:55:39 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farquhar John C.M. sold $657,005 worth of shares (22,562 units at $29.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 519,397 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/13/26 6:23:51 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Jones Marie L. covered exercise/tax liability with 567 units of Common Stock., decreasing direct ownership by 2% to 31,083 units (SEC Form 4) (withholding tax)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    5/8/26 6:47:10 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lightcap Jeffrey C bought $1,053,680 worth of shares (40,000 units at $26.34) (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    12/17/25 6:43:50 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Heartflow

    William Blair initiated coverage of Heartflow with a rating of Outperform

    5/4/26 8:35:19 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Heartflow with a new price target

    Wells Fargo initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    1/28/26 7:17:09 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.

    SCHEDULE 13G/A - Heartflow, Inc. (0001464521) (Subject)

    5/15/26 4:30:03 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Heartflow Inc.

    10-Q - Heartflow, Inc. (0001464521) (Filer)

    5/14/26 4:31:12 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Heartflow, Inc. (0001464521) (Filer)

    5/14/26 4:03:21 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

    SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt

    5/14/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Future of Intoxication Detection May Be in Your Voice

    AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming

    5/11/26 8:30:00 AM ET
    $BFLY
    $HTFL
    $RXRX
    Medical Electronics
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    $HTFL
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes

    MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to include former players from the National Basketball Association (NBA) and the National Hockey League (NHL), broadening Heartflow's initiative to protect the heart health of professional athletes across major sports. Retired NBA star Muggsy Bogues was one of the first former professional basketball players to join the GAMEFILM

    2/12/26 8:00:00 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Financials

    Live finance-specific insights

    View All

    Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

    SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt

    5/14/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026

    SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live an

    4/23/26 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts as of December 31, 2025U.S. Plaque installed base of 489 accounts as of December 31, 2025Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives

    3/18/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care